Psilocybin-assisted therapy shows promise for depression, though current evidence relies on Phase 2 trials with notable methodological limitations. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating psilocybin-assisted therapy for major or treatment-resistant depression up to February 2024. We evaluated depressive symptom severity using...
Depressive disorder is still a significant problem in several developed countriesand is morbidity caused by mental disorders. With the development of science,now discovered the unique pharmacodynamic properties of ketamine, which isused as an antidepressant. As we know in clinical practice, ketamine is used foranaesthesia, analgesia, sedation, and chronic pain management....